Conditions: Hypercholesterolemia
Keywords: Cholesterol High Cholesterol Elevated Cholesterol Raised Cholesterol
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 970
Healthy volunteers: no

Brief summary:
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery disease taking lipid lowering therapy.

Detailed description:

Arms:
arm 1: Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks. arm 2: Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.

Interventions: intervention 1: Evolocumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered by subcutaneous injection intervention 2: Administered by subcutaneous injection

Protocol document: